Tenaya Therapeutics grants inducement stock options under Nasdaq Rule 5635(c)(4) to attract new hires
Executive summary: Tenaya Therapeutics announced inducement stock option grants to new employees under Nasdaq Listing Rule 5635(c)(4). The grants indicate active hiring and may lead to modest shareholder dilution while reflecting confidence in the company’s prospects.
Who is involved: Tenaya Therapeutics, its board of directors, newly hired employees, Nasdaq
Likely next: The company will likely file a Form S‑8 to register the inducement shares; the options are expected to vest 25% after one year then monthly.
Tenaya Therapeutics disclosed that it has issued equity inducement awards to newly hired employees in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are intended to supplement compensation packages and are exempt from shareholder approval under the rule. The move signals the company’s ongoing hiring efforts as it advances its heart‑disease therapy pipeline.
Timeline
- — Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
- — Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Analysis — what this means
Likely next events
- Tenaya may file an S-8 registration statement within 30 days to cover the inducement shares
- The granted options are expected to vest 25% after one year, then monthly on a typical four-year schedule
Sectors affected
- Biotechnology
- Pharmaceuticals
Regulatory implications
- Compliance with Nasdaq Listing Rule 5635(c)(4) permits inducement grants without shareholder approval
- Any material change to the inducement plan must be disclosed in SEC filings
Historical parallels
- Geron Corporation inducement grant of 1,700,000 options on July 14, 2026 under the same Nasdaq rule